Within3 Announces New Round of Funding

Thu Dec 20, 2012 11:11am EST

* Reuters is not responsible for the content in this press release.

For best results when printing this announcement, please click on the link


New Capital Brings Aggregate Funding to $20 million
CLEVELAND,  Dec. 20, 2012  /PRNewswire/ -- Within3, the leading provider of
digital collaboration solutions for the pharmaceutical and life sciences
industries, today announced it has secured a new round of equity financing, led
by NY venture fund, Easton Capital. This round brings Within3's aggregate
funding to  $20 million  and continues Within3's expansion of its customer base
and supporting infrastructure.

"We are changing how the healthcare industry collaborates with their thought
leaders," said  Lance Hill, CEO, Within3. "The funding comes at a time when we
are gaining significant momentum in the marketplace. Our client base includes
ten of the Top 20 pharmaceutical companies, mid-tier pharmaceutical companies,
medical associations and hospitals, as well as large and boutique medical
communications companies."  

John H. Friedman, Managing Partner, Easton Capital Investment Group, stated, "As
a first-to-market company, we are impressed by Within3's vision of solving
critical business challenges through digital collaboration tools. We are pleased
to assist Within3 with the capital they need to help fill this need in the

About Within3

Within3 is the leading provider of digital collaboration solutions for the
health and life sciences markets. By utilizing Within3's innovative technology,
clients can efficiently convene and engage with groups of health professionals
from around the world. Strong support for privacy, regulatory, and security
standards underpin every implementation. By collaborating more effectively,
lower costs and better health outcomes are achieved. For more information, visit
 www.within3.com  or call 855-WITHIN3.

Ellynn Szoke
Chief Marketing Officer

SOURCE  Within3
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.